Innophore Bio Selected for Deloitte's 2025 China Rising Star in Life Sciences List, Pioneering a New Paradigm in NK Cell Therapy
iMBioRay
CAR-NK Cell Therapy Drug Developer
Recently, the "2025 Deloitte China Pharmaceutical Health Rising Star" list was officially announced, focusing on the most innovative and growth-potential pharmaceutical health enterprises from a global perspective.
Outstanding Enterprise in Guangdong Medical Valley —— Imbioray Successfully Ranks on the List with Breakthrough Technology in NK Cell Therapy, Global Pipeline Layout, and Commercialization Practice, Becoming a Representative of "Hard Technology" in the Cell Therapy Field.
This list
Extremely High Gold Content/
As one of the world's top four accounting firms, Deloitte's "Tomorrow's Star" selection has always been known for"Rigor, Prospectiveness, Authority"Known as the "benchmark for potential enterprises" in China's pharmaceuticals and healthcare industry, and praised as the "Oscar Award for high-growth enterprises in China."
The list of this edition started registration in May and underwent stringent screening by the evaluation committee from multiple dimensions. Its underlying "value" can be intuitively reflected in three major dimensions:
1. Screening Criteria: Focus on "Hard Innovation + Strong Resilience", Reject "Concept Hype"
The selection revolves around"Independent R&D Capability, Clear Clinical Value, Business Model Feasibility"Three Core Metrics Require Listed Companies to Excel in Niche FieldsEstablish Differentiation Advantages—— This means that companies with "no core technology, no clinical progress, and no commercialization path" cannot enter the review scope at all.
2. Listed Companies' Hard Power: High Valuation, Strong Sector, Innovation Focus
Data is the most convincing: among the companies on this year's list,Over 60% of valuations exceed 1 billion yuan,This means that these companies have crossed the "valley of death" in the start-up phase and entered a period of rapid growth. In terms of track distribution,80% is concentrated in the two core fields of innovative drugs and medical devices.It is precisely the track with the most vigorous innovation vitality in the current pharmaceuticals and healthcare industry.
3. Industry Trend Alignment: Enhanced Global Competitiveness of Innovative Drugs
The "2025 China Pharmaceutical Health Rising Star Project Report" released by Deloitte pointed out thatNew drugs are shifting from "quantitative accumulation" to "qualitative breakthrough," with technological accumulation and enhanced global competitiveness forming the core foundation of this qualitative change.The essence of making it to the list lies in the deep alignment between corporate strategy and the future direction of the industry.
Imbioray Makes the List with Strength
Four Core Advantages Build "NK Cell Therapy Barriers"/
In this list that brings together industry elites, the key reason why Imbioray stands out isImbioray has built a full-chain competitive advantage in the NK cell therapy field, covering "technology-pipeline-clinical translation-commercialization".Perfectly aligns with Deloitte's "Innovation + Resilience" selection criteria.
1. Technical Barriers: The World's Leading "Off-the-Shelf NK Cells" Solve Two Major Industry Pain Points
Unlike the limitations of traditional CAR-T therapy, which include "personalized customization, long production cycles, high costs, and potential gene-editing safety risks," Imbioray has chosen a "differentiated technical approach" —Non-viral vector, non-gene-edited antibody-cell conjugation technology not only enhances the cytotoxic activity of NK cells and achieves precise targeting but also fundamentally avoids the safety risks associated with gene editing.
More crucially, through four technological iterations, Imbioray has overcome the worldwide challenge of "difficult large-scale cultivation" of NK cells: establishing200-liter ultra-large production capacity system,Adopting GMP standardized production processes,A single batch has reached 90 billion cells, providing a stable supply for 100-150 treatments. Currently, in China, only Imbioray can achieve NK cell culture at such a large scale, with high purity and strong cytotoxicity.
This breakthrough has transformed NK cell therapy from "niche customization" to "universal off-the-shelf," significantly reducing the financial and time costs of immune cell therapy, and laying a core foundation for the "democratization" of cell therapy.
2. Pipeline Strength: 16 Pipelines + 4 Clinical Products, Covering Both Oncology and Non-Oncology "Dual Tracks"
Imbioray CurrentlyBuilt 16 product pipelines, with 4 products entering the clinical stage,The World's First Product Targeting 5T4 for Solid Tumor TreatmentHas entered the Phase II stage of registered clinical trials,Expected to rewrite the "difficult-to-breakthrough" pattern in solid tumor treatment.
More forward-looking, Imbioray will start from 2024 toThe pipeline has expanded from the oncology field to non-oncology fields.Covering autoimmune diseases (such as lupus, urticaria), chronic diseases (such as pulmonary nodules, hepatitis), and central nervous system diseases (such as Parkinson's, Alzheimer's), which not only expands the market space but also aligns with the industry trend of "precision medicine and full lifecycle management" mentioned in the Deloitte report.
3. Team Strength: Hardcore Team Safeguard
Imbioray has an elite team composed of top scientists from home and abroad.80% of the company's employees are R&D talents.Core members have深耕多年 in the field of innovative drugs and clinical translation.
Founder and CEO, Dr. Zhenwei MiaoPh.D. in Chemistry from Peking University, Postdoctoral Fellow at Vanderbilt University in the United States, has served as Chief Scientist in multiple NASDAQ-listed companies, successfully advancing several blockbuster drugs through clinical trials and to market,A global leader in the ADC field and a renowned expert in the antibody-conjugated NK cell domain.
In 2017, Imbioray had already hiredNobel Prize in Physiology/Medicine Laureate, the father of Swiss cytology, and an academician of multiple countries including the National Academy of Sciences of the United States, the German National Academy of Sciences, the Royal Society of the United Kingdom, and the Russian Academy of Sciences.Professor Rolf Zinkernagel serves as the Chief Scientific Advisor and Co-Director of the Joint Laboratory.
4.Capital Endorsement: "Quasi-Unicorn" with Nearly 400 Million in Financing
Imbioray's strength has also been highly recognized by the capital. So far, Imbioray's total financing has reached nearly 400 million yuan.Rated as a "Quasi-Unicorn Enterprise" and "IPO Listed Reserve Enterprise" by Hangzhou City, and selected into the Zhejiang Provincial Enterprise Research Institute.The continuous attention from capital stems from the confidence in Imbioray's technical roadmap and commercialization potential.
Currently, China's pharmaceuticals and health industry is moving from "China innovation" towards "global impact".Imbioray highlights its competitive advantage with "off-the-shelf NK cells," promotes the popularization of cell therapy through "scalable production capacity," and expands the boundaries of immune cell therapy with a "multi-field pipeline."
In the future, as dynamic supervision accelerates and global innovation resources flow, companies like Imbioray, which are rooted in technological innovation and possess commercial resilience, are expected to become a significant force in China's pharmaceuticals and healthcare industry "going global." Innovation knows no boundaries, resilience fosters growth— the future is already here.
